Datamonitor launches
Immune Disorders and Inflammation Review
The IDI Review brings you
the latest news, analysis and research covering immune disorders and
inflammation. It covers all the major current business issues and events,
including R&D, licensing deals, alliances and joint ventures, and
regulatory decisions.
Scope
-
Strategic insight
into the future shape of IDI companies and markets
-
The most significant
IDI industry news compiled into one monthly update
-
Expert analysis into
the implications of the month's important IDI industry events
-
Insight into the
future shape of the market for players at all levels
-
All the month's major
IDI stories in headline and summary form
Report Highlights
Out of the dozens of
topics covered in this month's review, the most important include:
-
Warner-Lambert (now
Pfizer) was accused of withholding documents showing the dangers
associated with the diabetes drug Rezulin from federal regulators. The
FDA now believes that the drug has been responsible for 94 individual
cases of liver failure and 66 deaths in the US.
-
Schering-Plough faces
a battle to maintain its exclusivity to the Claritin treatment, after
a US District Court Judge found that certain claims of a patent
protecting against generic versions of the nonsedating antihistamine
Claritin and expiring in 2004 were not valid.
Reasons to Purchase
Not only keeps you
updated about industry events - it also gives you opinion and insight
Draws upon Datamonitor
analysts' extensive experience to bring you our perspective on the impact
of the latest events
Provides you with your
own news archive to track company and industry progress, giving you an
extensive reference to relevant events and issues
View
pdf brochure
Click
here to purchase online
